23andMe Sale of Consumer Genetic Information to GlaxoSmithKline – Class Action Investigation

23andMe Sale of Consumer Genetic Information to GlaxoSmithKline –Class Action Investigation

Chimicles Schwartz Kriner & Donaldson-Smith LLP (CSK&D) is investigating recent reports that the mail-away gene-testing service 23andMe has agreed to sell five million consumers personal and family bio-information to British drug manufacturer GlaxoSmithKline Plc. GlaxoSmithKline recently confirmed that it agreed to invest $300 million in the Mountain View, California-based 23andMe and that Glaxo will be using this highly private information.

Reports indicate that not all consumers who signed up for 23andMe agreed that their personal bio-information can be used for research. 23andMe’s sale of consumer bio-information to GlaxoSmithKline may be a violation of consumer protection and consumer privacy laws. If you signed up for 23andMe and believe your information has been sold to GlaxoSmithKline or some other third-party without your consent, please contact the lawyers listed below.

(*) Indicates required field: When communicating with us through this site or otherwise in connection with a matter for which we do not already represent you, your communication may not be treated as privileged or confidential, and does not create an attorney-client relationship between you and our Firm.

Attorneys for this case:

Benjamin F. Johns
Andrew W. Ferich